What HydroDIURIL Treats: Main Uses and Benefits

HydroDIURIL (hydrochlorothiazide) is applied across domains where additional symptomatic support is needed. This medicine is relevant when supportive symptom management is appropriate, generally used in situations involving certain distressing symptoms.

It is commonly used across conditions presenting with acute episodes, especially when symptoms create noticeable physiological strain, such as those related to fluid accumulation (edema) and symptoms linked to heightened physiological activity (hypertension). It provides support that helps ease the overall symptom burden and supports patients during episodes of heightened discomfort.

Symptomatic Relief and Support

This supportive assistance is relevant for managing symptoms that interfere with daily comfort. It may be part of symptomatic management in situations where patients experience noticeable physiological strain.

Quick Fact: Relevant for Easing Symptom Clusters

The Key Benefit

The use of this medication contributes to improved comfort during symptomatic periods and may help patients cope more steadily with symptom fluctuations. This is particularly relevant in contexts involving heightened systemic burden, where short-term symptomatic assistance is needed.

Regulatory References

1. NIH MedlinePlus overview

Official Eligibility and Contraindications

HydroDIURIL (hydrochlorothiazide) is defined by regulatory bodies as contraindicated in specific patient populations. The medicine must not be used by individuals with Anuria (inability to urinate) or those with known hypersensitivity to the active ingredient or any sulfonamide-derived drugs.

Age- and Condition-Based Restrictions

Use is established for both adult and pediatric patients for the approved uses, though geriatric patients and certain pediatric groups may require specific caution. Use must be cautious and restricted in patients with:

• Severe Renal Disease or Impaired Hepatic Function, due to the risk of cumulative effects or complications like hepatic coma.
• Systemic Lupus Erythematosus (SLE), Gout or Hyperuricemia, and Diabetes Mellitus, as the drug may cause activation or exacerbation of these conditions.

Pregnancy and Lactation Status

The routine use of HydroDIURIL during an otherwise healthy pregnancy is classified as inappropriate by regulatory labeling, and use is generally only recommended if clearly needed. The medicine is excreted in breast milk, requiring a decision to discontinue either nursing or the drug due to the potential for serious adverse reactions in the nursing infant.

Interactions with other medicines and products

Official regulatory information for HydroDIURIL (Hydrochlorothiazide) documents specific interaction patterns that affect exposure, efficacy, or risk profile. These interactions are categorized based on their mechanism and outcome as described in regulatory labels.

Key Documented Interaction Patterns

Interaction Type	Interacting Substance/Class	Official Interaction Outcome
Exposure Alteration	Lithium	Reduced renal clearance, greatly increasing the risk of lithium toxicity.
Exposure Alteration	Cholestyramine or Colestipol resins	Reduced absorption of Hydrochlorothiazide.
Contraindicated Combination	Aliskiren	Prohibited in patients with diabetes due to high risk of adverse renal outcomes.
Pharmacodynamic Potentiation	Alcohol, Barbiturates, or Narcotics	Potentiation of orthostatic hypotension.
Efficacy Reduction	Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)	Possible loss of the antihypertensive and diuretic effect.
Electrolyte Intensification	Corticosteroids or ACTH	Intensified risk of electrolyte depletion, specifically hypokalemia.

Administration Requirements

To minimize the documented reduction in exposure, regulatory information specifies a mandatory separation when co-administering with certain resins. Hydrochlorothiazide must be taken at least one hour before or four hours after resins such as Cholestyramine. Furthermore, due to the critical toxicity risk, the combination with Lithium is generally advised against in regulatory documents. Thiazide diuretics must also be discontinued prior to conducting tests for parathyroid function.

Specific Inhibition of Renal Salt Transport

HydroDIURIL (hydrochlorothiazide) exerts its primary action by blocking the Sodium-Chloride Cotransporter (NCC), a specific protein found on the cells lining the Distal Convoluted Tubule of the kidney . This targeted inhibition prevents the reabsorption of sodium and chloride ions back into the blood, forcing the salt to remain in the kidney tubules. This molecular action immediately establishes an osmotic gradient.

---

Modulating Fluid Volume and Vascular Resistance

By retaining salt in the tubular fluid, the osmotic gradient causes water to follow, leading to increased urinary output (diuresis) and a reduction in the body's circulating fluid volume. The decrease in circulating fluid volume represents the initial physiological adjustment that results in reduced hydrostatic pressure. Over time, the mechanism also influences the distribution of electrolytes in the body, resulting in a crucial secondary effect: a decrease in the overall resistance of the blood vessels (vascular tone).

---

Adjustments to Electrolyte Balance

The drug's blockade of the NCC also causes secondary adjustments to other electrolyte pathways. Notably, it increases the excretion of potassium and hydrogen ions while uniquely promoting the reabsorption and conservation of calcium ions (Ca^2+) within the kidney. This modulation results in an altered handling of the body's fluid and mineral composition, which is an integral part of the mechanism.

Official Administration and Dosage Guidelines

HydroDIURIL (hydrochlorothiazide) is a medication that must be used strictly according to the prescribing information.

Dosing and Administration Schedule

The approved route of administration is oral (by mouth) as a tablet, capsule, or reconstituted oral suspension. Dosing is typically once daily, although some regimens may permit administration in two divided doses. It is often recommended taking the dose in the morning to avoid nocturnal diuresis.

Indication	Initial Adult Dose	Maintenance Dose Range	Maximum Daily Dose (Adults)
Hypertension	25 mg once daily	25 mg to 50 mg daily	50 mg (in combination with other agents)
Edema	25 mg to 100 mg daily	25 mg to 100 mg daily	200 mg

For edema, the dose may be administered on an intermittent schedule, such as on alternate days or for 3 to 5 days each week, which is a pattern often advised to reduce the risk of electrolyte imbalances.

Procedural and Population-Specific Instructions

The medicine may be administered with or without food. If using a powdered formulation, it must be reconstituted with water and shaken vigorously before dispensing.

For pediatric patients (children and infants), the dosage is typically calculated based on body weight, generally 1 to 2 mg/kg per day in a single or divided dose. Older adults may require careful dose titration and may be started on lower doses. In cases of severe renal impairment (creatinine clearance < 30 mL/min), hydrochlorothiazide is generally not recommended as it is considered ineffective.

If a dose is missed, it is generally advised to take it as soon as possible, unless it is almost time for the next scheduled dose, in which case the missed dose should be skipped.

Research evidence / Overview of Studies for HydroDIURIL

This overview is a summary of the official research that has been conducted on HydroDIURIL (hydrochlorothiazide). It describes the types of studies available, the specific patient populations they focused on, and what the collected evidence suggests regarding patterns observed, without offering any medical advice or treatment recommendations.

---

Evidence for Use in High Blood Pressure (Hypertension)

Research exploring this medication for high blood pressure relies primarily on Randomized Controlled Trials (RCTs) and systematic reviews. Studies monitored the measurement of changes in blood pressure and the frequency of major cardiovascular events (such as stroke and heart attack). Adult populations and pediatric patients was studied for this indication. Comparative research described patterns where related agents was associated with findings that varied from the results for this medication, and evidence quality varies across studies.

---

Evidence for Adjunctive Fluid Retention (Edema) Management

Research examined its use as an added treatment for fluid retention (edema) in conditions such as Congestive Heart Failure, specific kidney dysfunctions, or severe liver disease. Studies monitored changes in body weight and the measurement of changes in visible fluid accumulation. The existing evidence describes the agent's role in volume management as a component of broader treatment regimens. Research indicates that its utility may be limited in patients who have severe kidney impairment, where data for certain groups remain insufficient.

---

Long-Term Studies and Follow-Up Duration

For hypertension, the key randomized trials often monitored patients for intermediate periods, ranging up to around five years, to track cardiovascular outcomes. Research provides context but not individual predictions. Observations of blood pressure change may occur relatively quickly, but long-term effects on complex outcomes are not fully established beyond the observed trial periods.

---

Evidence in Special Populations

Research has explored the use of HydroDIURIL across different age groups. Pediatric patients and older adults was observed in the large-scale trials for hypertension. However, specific data examining the long-term impact on people with a very high number of comorbid conditions (multiple severe illnesses) are less well characterized. Subgroup findings are uncertain, and evidence remains limited for highly specific patient groups.

---

Evidence Quality, Consistency, and Key Limitations

Studies contribute to the broader evidence landscape. However, research highlights changes that indicate evidence quality varies across studies, particularly in comparative settings. Comparative evidence is lacking or inconsistent regarding certain outcomes; for instance, some analyses data show patterns related to different measured outcomes for stroke or heart attack when compared with related diuretics. The follow-up durations were limited in many studies, meaning long-term effects are not fully established.

Key Studies & References

1. Hydrochlorothiazide. In: StatPearls [Internet]. (General Review and Mechanism)
2. Hydrochlorothiazide Tablet, USP (Official FDA Label/Package Insert)

Common questions about HydroDIURIL (FAQ)

---

Q: Does HydroDIURIL help retain or excrete calcium and how does that affect my body?

Official regulatory information indicates that HydroDIURIL promotes the reabsorption of calcium ions in the kidney, meaning it helps the body retain calcium. This mechanism is sometimes cited in official literature as a potential factor in managing patients with high levels of calcium in their urine.

---

Q: How should I take HydroDIURIL with respect to my meals (with or without food)?

Regulatory documents state that this medication may be taken with or without food, giving flexibility for administration. The official prescribing information often notes that taking the dose in the morning is recommended to help minimize the need to urinate frequently during the night.

---

Q: Can taking HydroDIURIL increase my risk for skin cancer?

Official warnings mention that there is a recognized dose-related increased risk of Non-Melanoma Skin Cancer, including Basal Cell Carcinoma and Squamous Cell Carcinoma, associated with higher cumulative doses. Official information advises limiting sun exposure, and regular skin examinations may be recommended by a healthcare provider to monitor for any changes.

---

Q: Are there any dietary restrictions I should follow while taking this medication?

Official information emphasizes the importance of following any dietary instructions provided by a healthcare professional, especially regarding low-salt or low-sodium diets. This is also relevant if patients have been advised to increase their intake of potassium-rich foods to manage their electrolyte balance.

---

Q: What is the brand name of the HydroDIURIL generic equivalent?

The active ingredient in HydroDIURIL is hydrochlorothiazide, which is the generic name (often abbreviated as HCTZ). According to sources like the National Library of Medicine, other common brand names for this medicine include Microzide, Oretic, and Esidrix.

---

Q: How quickly does HydroDIURIL start to lower my blood pressure or reduce swelling?

The initial fluid-reducing effect (diuresis) begins relatively quickly, within 2 hours of taking the tablet, and its peak effect occurs in about 4 hours. However, the full blood pressure-lowering effect may take several weeks of consistent use to fully develop.

---

Q: Can I drink alcohol while taking my high blood pressure medicine, HydroDIURIL?

Official product information states that certain substances, including alcohol, barbiturates, or narcotics, may intensify the risk of orthostatic hypotension. This is a sudden drop in blood pressure that can occur when moving from a sitting or lying position to a standing position.

---

Q: What should I do if I think I am experiencing signs of Lithium toxicity?

Because HydroDIURIL can increase the risk of lithium toxicity when taken together, official patient information advises being aware of potential symptoms. These may include signs like nausea, vomiting, diarrhea, hand tremors, lack of coordination, or slurred speech, and individuals should contact a healthcare professional or seek medical attention if these occur.

---

Q: Is it common to have an allergic reaction to this medication?

Known hypersensitivity to hydrochlorothiazide or other sulfonamide-derived drugs is listed as a contraindication, meaning the drug must not be used by affected individuals. Although rare, very serious allergic reactions, including severe skin reactions like Stevens-Johnson syndrome, are documented as possible adverse effects.

Storage and Protection Requirements

HydroDIURIL (hydrochlorothiazide) tablets must be stored at Controlled Room Temperature (CRT), defined as 20^circ to 25 C (68^circ to 77 F). The official label permits temporary temperature excursions between 15^circ and 30 C (59^circ and 86 F).

To maintain product quality, the medication must be kept in a tight, light-resistant container. As a universal safety rule, all medicines must be stored out of the reach of children.

Official Disposal Rules

Disposal of unused or expired HydroDIURIL should follow established regulatory guidelines. The preferred method is returning the product through a local drug take-back program. If this is not an option, the medication can be discarded in the household trash after mixing it with an undesirable substance, such as used coffee grounds. Under no circumstances should this medicine be flushed down a toilet or poured into a drain.